Yarangümeli Alper, Comoglu Selçuk, Köz Ozlem Gürbüz, Elhan Atilla Halil, Kural Gülcan
Ankara Numune Training and Research Hospital, 1st Eye Clinic, Ankara, Turkey.
Doc Ophthalmol. 2003 May;106(3):265-70. doi: 10.1023/a:1022925432197.
Fifty-one patients with migraine were divided into four groups to investigate the effects of topical betaxolol and systemic calcium channel blocker flunarizine on visual fields (VF) and intraocular pressure (IOP). The first group (Group 0) was followed with no medications, topical betaxolol (bid) was precribed to the second group (Group B), oral flunarizine (10 mg daily) was prescribed to the third group (Group F), and the last group (Group BF) was assigned for combined betaxolol and flunarizine treatment. After a mean follow-up time of 4.2 +/- 1.2 months (3-6 months), IOP measurements and VF tests were repeated. Group B and Group BF were found to be statistically different from the other groups in terms of IOP reduction and VF improvement according to mean deviation and corrected pattern standard deviation indices in the second examinations. On the other hand, Group F and Group BF differed from the other two groups considering the improvement in migrainous complaints. VF findings which are probably influenced by perfusion problems due to vasospastic mechanisms in migraineurs, improved following topical betaxolol treatment. However, systemic use of flunarizine--a calcium channel blocker--did not seem to be effective on visual fields although it had beneficial effects on migraine.
51例偏头痛患者被分为四组，以研究局部使用倍他洛尔和全身性钙通道阻滞剂氟桂利嗪对视野（VF）和眼压（IOP）的影响。第一组（0组）不服药，第二组（B组）局部使用倍他洛尔（每日两次），第三组（F组）口服氟桂利嗪（每日10毫克），最后一组（BF组）采用倍他洛尔和氟桂利嗪联合治疗。在平均随访4.2±1.2个月（3 - 6个月）后，重复进行眼压测量和视野测试。根据第二次检查中的平均偏差和校正模式标准差指数，发现B组和BF组在眼压降低和视野改善方面与其他组存在统计学差异。另一方面，考虑到偏头痛症状的改善，F组和BF组与其他两组不同。偏头痛患者中可能由于血管痉挛机制导致灌注问题而受到影响的视野，在局部使用倍他洛尔治疗后得到改善。然而，全身性使用钙通道阻滞剂氟桂利嗪虽然对偏头痛有有益作用，但似乎对视野无效。
